Benton County gets eighth circuit judge
BENTON COUNTY, Ark. (KNWA/KFTA) — A new judge is coming to Benton County.
Senate Bill 234, now Act 220, creates an eighth circuit judgeship for the 19th Judicial District West to help manage the county's growing caseload.
The position takes effect April 1, 2025, and will be filled in the 2026 election. The elected judge will start on Jan. 1, 2027, with a six-year term.
Benton County couple pleads not guilty in baby sale attempt
Benton County will be responsible for providing courtroom space and staff, according to Act 220.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Perma-Pipe International Holdings, Inc. Announces the Departure of David Mansfield and the Appointment of Saleh Sagr as President and Chief Executive Officer
SPRING, Texas, June 12, 2025--(BUSINESS WIRE)--Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH, or "Perma-Pipe"), today announced the departure of David Mansfield as Chief Executive Officer ("CEO"), effective June 7, 2025. Concurrent with this announcement, the Board of Directors (the "Board") has appointed Saleh Sagr to serve as President and Chief Executive Officer. Chairman of the Board Jerome T. Walker commented: "On behalf of the Board of Directors, I want to thank David for his service to Perma-Pipe, and we wish him all the best. The Board is thrilled to welcome Saleh Sagr as our new CEO. He has a proven track record of strategic vision, operational insight, outstanding customer relationships, and strong leadership and we are confident that he will lead Perma-Pipe through continued growth and innovation." On his appointment, Mr. Sagr commented: "I am honored to be appointed CEO of Perma-Pipe, and I'm grateful to the Board for their trust and confidence in me. Additionally, I would like to thank David Mansfield for his support and trust. I look forward to collaborating closely with our talented global teams, customers, and partners to continue delivering value, innovation, and excellence across all markets we serve." Mr. Sagr joined Perma-Pipe in 2019 and has held several executive roles, most recently as President. Saleh brings over 30 years of international experience in operations, engineering, and executive leadership across the energy and infrastructure sectors. Perma-Pipe International Holdings, Inc. Perma-Pipe International Holdings, Inc. (Nasdaq: PPIH, "Perma-Pipe", or the "Company") is a global leader in pre-insulated piping and leak detection systems for oil and gas, district heating and cooling, and other applications. It uses its extensive engineering and fabrication expertise to develop piping solutions that solve complex challenges regarding the safe and efficient transportation of many types of liquids. In total, Perma-Pipe has operations at fourteen locations in six countries. Forward-Looking Statements Certain statements and other information contained in this press release that can be identified by the use of forward-looking terminology constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby, including, without limitation, statements regarding the expected future performance and operations of the Company. These statements should be considered as subject to the many risks and uncertainties that exist in the Company's operations and business environment. Such risks and uncertainties include, but are not limited to, the following: (i) the impact of the coronavirus ("COVID-19") on the Company's results of operations, financial condition and cash flows; (ii) fluctuations in the price of oil and natural gas and its impact on the customer order volume for the Company's products; (iii) the Company's ability to comply with all covenants in its credit facilities; (iv) the Company's ability to repay its debt and renew expiring international credit facilities; (v) the Company's ability to effectively execute its strategic plan and achieve profitability and positive cash flows; (vi) the impact of global economic weakness and volatility; (vii) fluctuations in steel prices and the Company's ability to offset increases in steel prices through price increases in its products; (viii) the timing of order receipt, execution, delivery and acceptance for the Company's products; (ix) decreases in government spending on projects using the Company's products, and challenges to the Company's non-government customers' liquidity and access to capital funds; (x) the Company's ability to successfully negotiate progress-billing arrangements for its large contracts; (xi) aggressive pricing by existing competitors and the entrance of new competitors in the markets in which the Company operates; (xii) the Company's ability to purchase raw materials at favorable prices and to maintain beneficial relationships with its suppliers; (xiii) the Company's ability to manufacture products free of latent defects and to recover from suppliers who may provide defective materials to the Company; (xiv) reductions or cancellations of orders included in the Company's backlog; (xv) the Company's ability to collect an account receivable related to a project in the Middle East; (xvi) risks and uncertainties related to the Company's international business operations; (xvii) the Company's ability to attract and retain senior management and key personnel; (xviii) the Company's ability to achieve the expected benefits of its growth initiatives; (xix) the Company's ability to interpret changes in tax regulations and legislation; (xx) the Company's ability to use its net operating loss carryforwards; (xxi) reversals of previously recorded revenue and profits resulting from inaccurate estimates made in connection with the Company's percentage-of-completion revenue recognition; (xxii) the Company's failure to establish and maintain effective internal control over financial reporting; and (xxiii) the impact of cybersecurity threats on the Company's information technology systems. Shareholders, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are made only as of the date of this press release and we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. More detailed information about factors that may affect our performance may be found in our filings with the Securities and Exchange Commission, which are available at and under the Investor Center section of our website ( View source version on Contacts Perma-Pipe International Holdings, Inc. Saleh Sagr, President and CEO Perma-Pipe Investor Relations 847.929.1200investor@
Yahoo
15 minutes ago
- Yahoo
Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders
Meeting to Reconvene on Wednesday, July 9, 2025 SAN DIEGO, June 12, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today announced that the company's 2025 annual meeting of stockholders (the 'Annual Meeting') was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting. There were fewer than a majority of shares entitled to vote present, either in person or by proxy, at the Annual Meeting. The Annual Meeting therefore had no quorum and was adjourned to allow time to solicit additional proxies on behalf of the company's board of directors. The Annual Meeting will reconvene at 9:00 a.m. Pacific Time on Wednesday, July 9, 2025, and will continue to be held virtually. Stockholders who have already submitted a proxy or voted do not need to vote again, as proxies and votes previously submitted in respect of the Annual Meeting will remain valid at the reconvened Annual Meeting unless properly revoked. The record date for determining stockholders eligible to vote at the reconvened Annual Meeting remains April 17, 2025. Stockholders as of close of business on the April 17, 2025 record date who have not yet voted are encouraged to vote online at or by telephone at 1-800-690-6903. Please vote by 11:59 p.m. Eastern Time on July 8, 2025. If you hold your shares of the company's common stock in an account at a brokerage firm, bank, dealer or other similar organization, you may be subject to an earlier voting deadline and you should carefully review any materials received from the organization holding those shares regarding how to vote to ensure your vote is counted. A copy of the company's definitive proxy statement for the Annual Meeting is available to stockholders on on the Company's website at and on the website maintained by the U.S. Securities and Exchange Commission ('SEC') at Daré Bioscience stockholders as of close of business on the April 17, 2025 record date for the Annual Meeting, or their legal proxy holders, will be able to attend the reconvened Annual Meeting by visiting Important Information This material may be deemed to be solicitation material in respect of the Annual Meeting to be reconvened and held on Wednesday, July 9, 2025. In connection with the Annual Meeting, the company filed a definitive proxy statement with the SEC on April 24, 2025. BEFORE MAKING ANY VOTING DECISION, THE COMPANY URGES ITS STOCKHOLDERS TO READ THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING. The definitive proxy statement was sent or made available to stockholders entitled to vote at the Annual Meeting on or about April 24, 2025. No changes have been made to the proposals to be voted on by stockholders at the Annual Meeting. A copy of the definitive proxy statement and any other materials filed by the company with the SEC can be obtained free of charge at the SEC's website at or the company's website at About Daré Bioscience Daré Bioscience is a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority. Daré believes that innovation does not have to start from scratch. The company's goal is to bring to market as soon as practicable innovative evidence-based solutions that address decades of unmet needs in women's health and enhance outcomes and convenience, primarily in the areas of contraception, sexual health, pelvic pain, fertility, infectious disease, vaginal health and menopause. The potential products Daré identifies, in many cases, already have clinical proof of concept or existing safety data for the active ingredient that the company leverages. This provides optionality and flexibility, in many cases, in how Daré seeks to bring solutions to market in ways designed to optimize access for women in a fiscally responsible manner. The first FDA-approved product to emerge from Daré's portfolio of women's health product candidates is XACIATO™ (clindamycin phosphate) vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Visit for information about XACIATO. Daré's portfolio also includes potential first-in-category candidates in clinical development: Ovaprene®, a novel, hormone-free monthly intravaginal contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil citrate, the active ingredient in an oral erectile dysfunction drug for men, to treat female sexual arousal disorder (FSAD); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy. To learn more about Daré's full portfolio of women's health product candidates and mission to deliver differentiated therapies for women, please visit Daré Bioscience leadership has been named on the Medicine Maker's Power List and Endpoints News' Women in Biopharma and Daré's CEO has been honored as one of Fierce Pharma's Most Influential People in Biopharma for Daré's contributions to innovation and advocacy in the women's health space. Daré may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website ( SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these X (formerly Twitter) accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Daré's website. Contacts: Daré Bioscience Investor Relationsinnovations@ Source: Daré Bioscience, in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26 minutes ago
- Yahoo
Trump on ‘No Kings' protests during military parade: ‘I don't feel like a king'
President Trump was asked Thursday to respond to planned counterprotests that will coincide with a military parade in the nation's capital to mark the U.S. Army's 250th birthday. When asked to respond to the anti-Trump 'No Kings' demonstrations expected around the country, Trump quipped: 'I don't feel like a king; I have to go through hell to get stuff approved.' 'A king would say, 'I'm not going to get this.' A king would have never had the California mandate to even be talking, he wouldn't have to call up [Speaker] Mike Johnson and [Senate Majority Leader John] Thune and say, 'fellas you got to pull this off' and after years we get it done,' he added. 'No, no we're not a king. We're not a king at all.' The president was referencing a congressional resolution he had just signed that overturns a California state rule that would have phased out the sale of new gas-powered cars by 2035. The Biden administration approved California's rule late last year, which is what Trump's signature officially revokes. California has already said it would sue the Trump administration over the move. Organizers with the No Kings movement are planning some 1,500 demonstrations in cities nationwide, excluding Washington, D.C., where the military parade is set to take place. The parade marks the 250th birthday of the U.S. Army, and it also falls on Trump's 79th birthday. The president is expected to attend and give remarks. Trump on Tuesday warned protesters that they would be met with 'very big force' if they demonstrate at the upcoming D.C. parade. White House press secretary Karoline Leavitt was asked if Trump would support having 'peaceful' protesters Saturday, and she slammed the reporter over the questioning. 'Of course the president supports peaceful protests. What a stupid question,' Leavitt said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
